287 related articles for article (PubMed ID: 2068099)
21. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
23. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
24. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
[TBL] [Abstract][Full Text] [Related]
25. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals.
Hariharan K; Nara PL; Shabazz LA; McCutchan JA; Kang CY
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1629-37. PubMed ID: 7888222
[TBL] [Abstract][Full Text] [Related]
26. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
McKeating JA; Cordell J; Dean CJ; Balfe P
Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
[TBL] [Abstract][Full Text] [Related]
28. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
[TBL] [Abstract][Full Text] [Related]
29. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.
Burkly L; Mulrey N; Blumenthal R; Dimitrov DS
J Virol; 1995 Jul; 69(7):4267-73. PubMed ID: 7769687
[TBL] [Abstract][Full Text] [Related]
31. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
32. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
Bou-Habib DC; Roderiquez G; Oravecz T; Berman PW; Lusso P; Norcross MA
J Virol; 1994 Sep; 68(9):6006-13. PubMed ID: 8057475
[TBL] [Abstract][Full Text] [Related]
33. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
Binley JM; Lybarger EA; Crooks ET; Seaman MS; Gray E; Davis KL; Decker JM; Wycuff D; Harris L; Hawkins N; Wood B; Nathe C; Richman D; Tomaras GD; Bibollet-Ruche F; Robinson JE; Morris L; Shaw GM; Montefiori DC; Mascola JR
J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292
[TBL] [Abstract][Full Text] [Related]
34. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
[TBL] [Abstract][Full Text] [Related]
35. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
36. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
Moore JP; Cao Y; Ho DD; Koup RA
J Virol; 1994 Aug; 68(8):5142-55. PubMed ID: 8035514
[TBL] [Abstract][Full Text] [Related]
37. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
Callahan LN; Phelan M; Mallinson M; Norcross MA
J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
[TBL] [Abstract][Full Text] [Related]
38. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
39. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.
Arendrup M; Akerblom L; Heegaard PM; Nielsen JO; Hansen JE
Arch Virol; 1995; 140(4):655-70. PubMed ID: 7794110
[TBL] [Abstract][Full Text] [Related]
40. Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.
Broliden PA; Mäkitalo B; Akerblom L; Rosen J; Broliden K; Utter G; Jondal M; Norrby E; Wahren B
Immunology; 1991 Aug; 73(4):371-6. PubMed ID: 1916888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
